Divi’s Labs

Analysts' average price target of Rs 3,862, however, indicates significant upside. The near-term trend remains bearish

EBITDA margins declined 767 bps YoY to 33.5 per cent due to high energy and transport costs.

Valuations, too, are on the higher side, say brokerages

The world's race for a coronavirus drug hinges on Indian companies working with their global peers. Business Standard tracks six companies to feel the pulse of Indian pharma

Brokerages expect the company's net profits to grow by 30 per cent annually over FY20-23

According to Axis Securities, the small and midcaps are picking up steam and they should deliver solid returns in 2021 as economic uncertainties will reduce and volatility will decline

Divi's Laboratories, established in Hyderabad, is a pharmaceutical company with two manufacturing units

Niche capabilities and absence of regulatory overhangs are other key positives

The current margin pressure will also get mitigated by tax benefits and operational efficiencies

The Company's Unit-I facility at Lingojigudem, Bhuvanagiri Yadadri district, Telangana has been inspected by the USFDA from the November 11, to November 15, 2019.

The company had posted a net profit of Rs 403.72 crore in the July-September period of 2018-19.

The second largest pharma player by market value is also expanding capacities to push earnings

According to Divis latest annual report, Murali Divi, the promoter-executive,was given a hike of 46.3 per cent in his remuneration over the previous fiscal

Higher raw material costs fuelled by the rising Chinese chemical prices were the major reason for margins disappointment

The stock surged 14% to Rs 1,433 on the BSE in early morning trade on Monday, after reported a healthy 92% Y-o-Y jumped in net profit at Rs 3.98 billion in September quarter.

This is seen as unprecedented for Indian drug makers

At NSE, shares of the company jumped 6.44% to touch its one-year high of Rs 1,271

Total income from operations at Rs 1,008 crore, up 25%; expenditure during this period grew by 18.4%